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ABSTRACT
Background: Hydrofluoroalkane-134a (HFA) has been shown to be a safe replacement for chlorofluorocar-
bons (CFCs) as a pharmaceutical propellant, with the advantage that it has no ozone-depleting potential. This
is the first report of the pharmacokinetics of beclomethasone dipropionate (BDP) delivered from a pressurized
solution formulation using an HFA propellant system (HFA-BDP) in Japanese children with bronchial asthma.
Methods: Plasma concentrations of beclomethasone 17-monopropionate (17-BMP),a major metabolite of
BDP, following an inhaled dose of HFA-BDP (200 μg as four inhalations from 50 μgactuation) in five Japanese
children with bronchial asthma were quantified and analyzed by a non-compartmental analysis to obtain phar-
macokinetic parameters.
Results: The area under the concentration-time curve from time zero to the last quantifiable time (AUC0-t) was
1659 ± 850 pg・hmL (arithmetic mean ± standard deviation (SD)), the maximum concentration observed
(Cmax) was 825 ± 453 pgmL and the apparent elimination half-life (t12) was 2.1 ± 0.7 hours. The time to reach
Cmax (Tmax) was 0.5 hours in all patients. No special relationship was observed between these parameters and
age or body weight. These parameters were compared with the previously reported parameters of American
children with bronchial asthma. The JapaneseAmerican ratio of the geometric means of each parameter was
1.36 for AUC0-t, 1.04 for Cmax and 1.4 for t12. The median of Tmax was 0.5 hours in American patients as well as
Japanese patients.
Conclusions: The pharmacokinetics of HFA-BDP in Japanese children with bronchial asthma are reported for
the first time and a similarity to those in American children is suggested.
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INTRODUCTION
Hydrofluoroalkane-134a (HFA) has been shown to be
a safe replacement for chlorofluorocarbons (CFCs) as
a pharmaceutical propellant, with the advantage that
it has no ozone-depleting potential.1 Metered dose in-
halers ( MDIs ) of beclomethasone dipropionate
(BDP), using CFCs as propellant system in a press-
and-breathe (P&B) inhalation device (CFC-BDP) ,
have been used for many years in patients with bron-
chial asthma, but the Montreal Protocol represents
international agreement to cease CFCs production
and use. HFA is a suitable replacement propellant for
CFCs in MDIs, as it does not deplete stratospheric
ozone. The BDP solution product using HFA as pro-
pellant system (HFA-BDP) has a smaller particle size
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Fig. 1 Individual (○) and mean (●) plasma concentration-
time profiles of beclomethasone 17-monopropionate (17-
BMP) in Japanese children with bronchial asthma folowing 
administration of 200 μg of beclomethasone dipropionate 
(BDP). Each eror bar represents the standard deviation.
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distribution (by mass) than the CFC-BDP suspension
product , which results in improved intrapulmonary
deposition and airway availability of HFA-BDP when
compared with CFC-BDP . 2 The HFA-BDP has an
equivalent effect to the twice dose of CFC-BDP3 and
has been approved and used in adult patients in nu-
merous countries. As CFC-BDP has also been essen-
tial in the treatment of children with bronchial
asthma, the indications and usage of HFA-BDP for
children need to be established urgently. Although
the pharmacokinetics of HFA-BDP in American chil-
dren with bronchial asthma have already been re-
ported,4,5 they have not yet been reported in Japanese
children. The objective of this clinical trial was to clar-
ify the pharmacokinetics of HFA-BDP in Japanese
children with bronchial asthma.
METHODS
Five Japanese patients with stable mild asthma, be-
tween the ages of 6 years and 15 years (3 men and 2
women), were enrolled in this open-label study. Writ-
ten informed consent was obtained from all patients
and their parents or legal guardians in accordance
with the Declaration of Helsinki . The independent
medical ethics review committee of Gifu University
approved the protocol. Each patient received 200 μg
BDP per period, as four inhalations of 50 μgactua-
tion P & B. Time zero for each dose was defined as
the time when the inhaler was first actuated. Blood
samples were collected before administration, and at
0.5, 1, 2, 4, 6, 9, 12 and 24 hours after administration.
Immediately after collection, the tube was inverted
and the blood was cooled on ice and centrifuged at
2000 rpm for 10 minutes at 7℃ , and the isolated
plasma was pippeted into two tubes ( 0.5 mL per
tube). In each tube, 15 μL of acetic acid was added
and mixed. Mixed samples were frozen immediately
in a dry icemethanol bath and stored frozen at under
−70℃ until analysis. As almost all the BDP-derived
material in plasma is reported to be the active me-
tabolite , beclomethasone 17-monopropionate ( 17-
BMP), 4 the plasma 17-BMP concentration was deter-
mined using an LCMSMS method with a lower
limit of quantitation of 75 pgmL developed by Harri-
son et al.5 with a few modifications. The pharmacoki-
netic parameters , area under concentration-time
curve from time zero to the last quantifiable time
(AUC0-t), maximum concentration observed (Cmax),
time to reach Cmax (Tmax) and apparent elimination
half-life ( t12) were calculated by a non-compart-
mental analysis of each plasma concentration-time
profile using WinNonlin ver.4.0 (Pharsight Corpora-
tion). The effects of age (6 to 14 years) and body
weight (22.8 to 85.0 kg) on AUC0-t, Cmax and t12 were
analyzed by linear regression analysis of log-
transformed parameters against age or body weight.
The parameters of Japanese children obtained in
this study were compared with the previously re-
ported parameters of American children with bron-
chial asthma provided by 3M Pharmaceuticals
(USA).6 For log-transformed parameters of AUC0-t,
Cmax and t12, means and their 90% confidence inter-
vals were calculated for the differences between Japa-
nese and American parameters and back-transformed
to geometric means and their 90% confidence inter-
vals for the ratios of Japanese parameters to Ameri-
can parameters . The log-transformed means of pa-
rameters were also compared by Student’s t-test, con-
sidering p values of less than 0.05 to indicate statisti-
cally significant differences.
RESULTS AND DISCUSSION
PHARMACOKINETICS OF HFA-BDP IN JAPA-
NESE CHILDREN WITH BRONCHIAL ASTHMA
The individual plasma concentration profiles of 17-
BMP in Japanese children with bronchial asthma and
their mean profile are shown in Figure 1. Pharma-
cokinetic parameters are shown in Table 1. The arith-
metic mean ± standard deviation (SD) of AUC0-t was
1659 ± 850 pg・hmL, Cmax was 825 ± 453 pgmL and
t12 was 2.1 ± 0.7 hours. Tmax was 0.5 hours in all pa-
tients. The coefficient of variability of AUC0-t and Cmax
(51.2% and 54.9%, respectively) was larger than that of
t12 (31.4%), which indicated a higher variability of the
rate and extent of absorption than the elimination
rate, possibly because of variability in the patients’ in-
halation techniques. No significant effect of age (6 to
14 years) or body weight (22.8 to 85.0 kg) on pharma-
cokinetic parameters was observed (Table 2, p =
0.145). This result suggests that no dose adjustment
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Fig. 2 Japanese (● ) and American (○ ) plasma 
concentration-time profiles of beclomethasone 17-mono-
propionate (17-BMP) folowing administration of 200 μg be-
clomethasone dipropionate (BDP). Each point represents 
the mean ± standard deviation of 5 Japanese or 18 Ameri-
can children with bronchial asthma.
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Table 1 Pharmacokinetic parameters of beclomethasone 17-monopropionate (17-BMP) in Japanese children with bronchial 
asthma folowing administration of 200 μg beclomethasone dipropionate (BDP)
t1/2
(h)
Tmax
(h)
Cmax
(pg/mL)
AUC0-t
(pg・h/mL)
Body weight
(kg)
Age
(years)
SexSubject
 1.70.51565306225.4 6Male1
 2.10.5 703146236.3 9Female2
 2.80.5 828152485.014Female3
 1.20.5 699150722.8 9Male4
 2.60.5 331 74127.411Male5
 2.10.5 825165939.410Mean
 0.7NC 453 850NCNCSD
31.4NC    54.9    51.2NCNCCV (%)
 2.0NC 7321501NCNCGeometric mean
AUC0-t, area under concentration-time curve; Cmax, maximum concentration observed; Tmax, time reach to Cmax; t1/2, apparent elimina-
tion half-life.
SD, standard deviation; CV, coeficient of variability.
NC, not calculated.
Table 2 Efects of age and body weight on pharmacokinetic 
parameters of beclomethasone 17-monopropionate (17-BMP) 
in Japanese children with bronchial asthma
t1/2CmaxAUC0-t
0.1450.2880.216Age
0.2030.9510.833Body weight
Each value represents the p-value from regression analysis 
of each parameter against age or body weight of 5 patients in 
this study.
AUC0-t, area under concentration-time curve; Cmax, maximum 
concentration observed; t1/2, apparent elimination half-life.
based on age or body weight in the range of this
study is needed , though much more data are re-
quired to derive a conclusion.
COMPARISON OF HFA-BDP PHARMACOKINET-
ICS BETWEEN JAPANESE AND AMERICAN
CHILDREN WITH BRONCHIAL ASTHMA
The plasma concentration profiles of 17-BMP in Japa-
nese and American children with bronchial asthma
following a 200 μg BDP dose using the HFA-
propellant system are shown in Figure 2. Pharma-
cokinetic parameters and their ratios ( Japanese
American) are shown in Table 3. The differences of
log-transformed mean 17-BMP parameters (AUC0-t,
Cmax and t12) between Japanese and Americans were
not significant (p = 0.13 ) . The median of Tmax in
American children was the same as that in Japanese
children. The estimated JapaneseAmerican AUC0-t
ratio was 1.36 with a 90% confidence interval of 0.870
to 2.13. The estimated JapaneseAmerican Cmax ratio
was 1.04 with a 90% confidence interval of 0.671 to
1.62. The estimated JapaneseAmerican t12 ratio was
1.4 with a 90% confidence interval of 0.96 to 1.9. All
confidence intervals contained 1, suggesting the pos-
sibility of the equivalence of the parameters between
Japanese and Americans. The wide confidence inter-
vals obtained may be due to variability in patients’ in-
halation techniques, and an insufficient limit of quan-
titation, which may affect the last quantifiable time-
point and the apparent elimination half-life.
In conclusion, the pharmacokinetics of HFA-BDP
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Table 3 Comparison of plasma pharmacokinetics of beclomethasone 17-monopropionate (17-BMP) between Japanese and 
American children with bronchial asthma folowing administration of 200 μg beclomethasone dipropionate (BDP)
t1/2TmaxCmaxAUC0-t
Country (h)(h)(pg/mL)(pg・h/mL)
2.00.5 (median)7321501Geometric mean
2.6)―(1.50.5)―(0.51079)―(4972224)―(101390% confidenceJapanese
max)―(mininterval
1.50.5 (median)7031102Geometric mean
1.8)―(1.21.0)―(0.08867)―(5701365)―(89190% confidenceAmerican
max)―(mininterval
1.41.0 (median ratio)1.041.36Geometric meanJapanese/
1.9)―(0.961.62)―(0.6712.13)―(0.87090% confidenceAmerican
intervalratio
AUC0-t, area under concentration-time curve; Cmax, maximum concentration observed; Tmax, time reach to Cmax; t1/2, apparent elimination 
half-life.
in Japanese children with bronchial asthma were in-
vestigated and the following parameters (arithmetic
mean ± SD or median for Tmax) were obtained; AUC0-t
(1659 ± 850 pg・hmL), Cmax (825 ± 453 pgmL), t12
(2.1 ± 0.7 hours) and Tmax (0.5 hours). These parame-
ters were similar to those of American children with
bronchial asthma.
In this study , the pharmacokinetic properties of
HFA-BDP did not show much difference between the
two countries. Therefore , propellant systems using
CFCs should be replaced by systems using HFA as
soon as possible in countries where such products
have already been launched, from the standpoint of
protection of the ozone layer. In addition, the intro-
duction of HFA products, e.g. HFA-BDP, is strongly
recommended in countries where such products are
not clinically available.
REFERENCES
1. Alexander DJ, Libretto SE. An overview of the toxicology
of HFA-134a (1, 1, 1, 2-tetrafluoroethane). Hum. Exp. Toxi-
col. 1995;14:715-720.
2. Leach CL, Davidson PJ, Boudreau RJ. Improved airway
targeting with the CFC-free HFA-beclomethasone me-
tered-dose inhaler compared with CFC-beclomethasone.
Eur. Respir. J. 1998;12:1346-1353.
3. Gross G, Thompson P, Chervinsky P, Vanden Burgt J,
Study Group. Hydrofluoroalkane-134a beclomethasone di-
propionate, 400 μg, is as effective as chlorofluorocarbon
beclomethazone dipropionate, 800 μg, for the treatment
of moderate asthma. Chest 1999;115:343-351.
4. Harrison LI, Kurup S, Chen LZ et al. Pharmacokinetics of
beclomethasone dipropionate ( BDP ) and metabolites
from CFC-free BDP Autohaler in asthmatic children. J. Al-
lergy Clin. Immunol. 1999;103:S128-S129.
5. Harrison LI, Kurup S, Chen LZ, Ekholm BP, Wighton TG,
Shapiro GG. Pharmacokinetic comparison of beclometha-
sone dipropionate extrafine aerosol from two inhaler de-
vices in children with asthma. Eur. J. Clin. Pharmacol.
2002;58:191-195.
6. Senta T, Harrison L, Kurup S et al. Comparative absorp-
tion study of HFA-134a beclomethasone dipropionate deliv-
ered from a press-and-breathe metered dose inhaler and
AutohalerTM inhalation device in a pediatric population
with reversible obstructive airway disease. Final Report. Re-
port Number: 1242-BRON. 3M Pharmaceuticals (USA),
1997.
320 Allergology International Vol 55, No3, 2006 www.jsaweb.jp
Teramoto T et al.
